Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

April 17, 2019

BioAtla and BeiGene Enter Collaboration to Develop BioAtla’s BA3071 Cancer Therapy

News

BioAtla and BeiGene entered into a collaboration agreement for the development, production, and commercialization of BioAtla’s BA3071, an investigational anti-CTLA-4 checkpoint blockade antibody. Checkpoint blockade therapies are based on the ... Read more

April 16, 2019

VB10.NEO and NKTR-214 Work Together to Drive Complete, Durable Tumor Regression, Study Says

News

Vaccibody‘s VB10.NEO and Nektar Therapeutics‘ bempegaldesleukin (NKTR-214 or bempeg) work together to trigger a strong immune response against cancer cells, resulting in complete and durable tumor regression in a mouse ... Read more

October 10, 2018October 10, 2018

2 Immunologists Win Nobel Prize in Medicine for Groundbreaking Cancer Research

News

Two immunologists, James Allison of the United States and Tasuku Honjo of Japan, have won the 2018 Nobel Prize in Medicine. Allison and Honjo will share the Nobel Prize sum ... Read more

September 28, 2018September 28, 2018

Imfinzi Prolongs Overall Survival in Advanced NSCLC Patients, Phase 3 Trial Data Show

News

Treatment with Imfinzi (durvalumab) significantly prolongs overall survival among patients with stage III, inoperable non-small-cell lung cancer (NSCLC) in comparison to those given a placebo, according to new data from ... Read more

June 27, 2018June 27, 2018

DNA Vaccine To Be Tested in Advanced Colorectal Cancer Patients for 1st Time in Phase 1/2 Trial

News

Researchers in Australia are testing for a first time the safety and efficacy of a DNA-based vaccine to treat advanced colorectal cancer in people with this disease, after promising results in ... Read more

June 20, 2018

Older Melanoma Patients Respond Better to Anti-PD-1 Immunotherapies, Study Shows

News

Older melanoma patients respond better to the anti-PD-1 immunotherapy Keytruda (pembrolizumab), according to new data from a multinational study. Researchers are attributing these differences to a reduced immunosuppressive tumor environment in ... Read more

June 13, 2018June 13, 2018

Men, Women Respond Differently to Immunotherapies Used in Advanced Cancer Treatment, Study Shows

News

Men and women may benefit differently from immunotherapy medications used to treat several types of advanced cancers, according to a review study. The study, “Cancer immunotherapy efficacy and patients’ sex: a ... Read more